Evidence map›Paper›PMID 40695831›Full record

ArticleNature communications2025

Specific oncogene activation of the cell of origin in mucosal melanoma.

Swathy Babu, Jiajia Chen, Chloé S Baron, Kaiwen Sun, Emily Robitschek, Alicia M McConnell, Constance Wu, Aikaterini Dedeilia, Moshe Sade-Feldman, Rodsy Modhurima and 13 more

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Swathy BabuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0612-9484
Jiajia ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5378-6284
Chloé S BaronStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8351-4768
Kaiwen SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Emily RobitschekDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alicia M McConnellStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.
Constance WuStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.
Aikaterini DedeiliaMassachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, MA, USA.
Moshe Sade-FeldmanMassachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0022-0287
Rodsy ModhurimaStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.
Michael P ManosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0841-207X
Kevin Y ChenStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.
Anna M CoxDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Calvin G LudwigStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1938-4273
Manolis KellisBroad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7113-9630
Elizabeth I BuchbinderDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nir HacohenMassachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2349-2656
Jiekun YangBroad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Genevieve M BolandMassachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7522-6173
Brian J AbrahamDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-8085-3027
David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0346-5033
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, USA. leonard.zon@enders.tch.harvard.edu.
Megan L InscoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Megan_Insco@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-6078-6506

Funding

EDAC: ENCODE Data Analysis CenterU24HG009446 · NHGRI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GERSTEIN, MARK BENDER, WENG, ZHIPING · 2017 to 2022
$10.4M
Predicting the impact of genetic variants, genes and pathways on human DiseaseU01HG012009 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI ALKES L PRICE, Soumya Raychaudhuri · 2021 to 2026
$4.2M
Construction of an Integrated Immune-Vascular Brain - Chip as a Platform for the Study, Drug Screening, and Treatments of Alzheimer's DiseaseUH3NS115064 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BLANCHARD, JOEL WILLIAM, KELLIS, MANOLIS · 2021 to 2023
$3.5M
Single-cell multi-region transcriptional and epigenomic dissection of VCID.RF1NS129032 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEIMAN, MYRIAM, KELLIS, MANOLIS · 2022 to 2022
$3.1M
Construction of an integrated immune - vascular brain - chip as a platform for the study, drug screening, and treatments of Alzheimer's diseaseUG3NS115064 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BLANCHARD, JOEL WILLIAM, KELLIS, MANOLIS · 2019 to 2020
$2.5M
Interpreting non-coding variants using epigenomics, regulatory models, & validation experimentsR01HG008155 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS · 2015 to 2017
$2.3M
Evaluating Pathways Involved in Melanoma InitiationR01CA295865 · NCI · BOSTON CHILDREN'S HOSPITAL · PI LEONARD Ira ZON · 2025 to 2026
$1.4M
Harvard Training Program in Bioinformatics Applied to Diabetes, Obesity and Metabolism.T32DK110919 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS, PATEL, CHIRAG J. · 2017 to 2021
$1.3M
Investigating Transcriptional Elongation and Nuclear RNA Surveillance in MelanomaK08CA248727 · NCI · DANA-FARBER CANCER INST · PI INSCO, MEGAN LEIGH · 2021 to 2025
$980k
NCI NIH HHS K08 CA248727NCI NIH HHS R01 CA295865NHGRI NIH HHS R01 HG008155NHGRI NIH HHS U01 HG012009NHGRI NIH HHS U24 HG009446NIDDK NIH HHS T32 DK110919NINDS NIH HHS RF1 NS129032NINDS NIH HHS UG3 NS115064NINDS NIH HHS UH3 NS115064
6 · The paper itself

Abstract

Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we develop a zebrafish model in which all melanocytes experience CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only develops from melanocytes lining internal organs, analogous to the location of patient MM. We find that zebrafish MMs have a unique chromatin landscape from cutaneous melanomas. Internal melanocytes are labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes share a gene expression signature with MMs. Patient and zebrafish MMs show increased migratory neural crest and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests that the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery. As this is a non-MAPK driven genetically engineered model of melanoma, our work also has implications for the 15% of cutaneous melanoma patients who lack MAPK-driving mutations.

Indexed as

MelanocytesMelanomaMucous MembraneOncogenesSkin NeoplasmsAnimalsChromatinCyclin D1Disease Models, AnimalGene Expression Regulation, NeoplasticHumansNeural CrestPTEN PhosphohydrolaseTumor Suppressor Protein p53ZebrafishZebrafish ProteinsChromatinCyclin D1PTEN PhosphohydrolasePTEN protein, humanTumor Suppressor Protein p53Zebrafish Proteins

Identifiers

PMID40695831
PMCPMC12284105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.